Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GLP1R | P43220 | 8/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL861319 | 1.00 | KMT2A (0.54) | KMT2AMEN1FAAHMAPK1GLP1R | |
| SCHEMBL25532300 | 0.98 | KMT2A (0.51) | KMT2AMEN1FAAHMAPK1GLP1R | |
| SCHEMBL14728075 | 0.95 | KMT2A (0.50) | KMT2AMEN1FAAHMAPK1GLP1R | |
| SCHEMBL25637029 | 0.88 | KMT2A (0.51) | KMT2AMEN1GLP1RALDH1A1HPGD | |
| SCHEMBL20458026 | 0.85 | MEN1 (0.47) | KMT2AMEN1FAAHMAPK1ALDH1A1 | |
| SCHEMBL24500907 | 0.85 | KMT2A (0.56) | KMT2AMEN1GLP1RALDH1A1SMN1; SMN2 | |
| SCHEMBL18908674 | 0.84 | KMT2A (0.73) | KMT2AMEN1MAPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL18908735 | 0.84 | KMT2A (0.73) | KMT2AMEN1MAPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL10447931 | 0.84 | KMT2A (0.73) | KMT2AMEN1MAPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL26249106 | 0.84 | MEN1 (0.46) | KMT2AMEN1FAAHMAPK1GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10039816-B2 | Siderophore-based immunization against gram-negative bacteria | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-08-07 | — | — | US | disclosed |
| US-9902986-B2 | Enterobactin conjugates and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10039816-B2 | Siderophore-based immunization against gram-negative bacteria | SLC40A1, SFXN1, SLC75A1 | KMT2A 4049/4885MEN1 2216/4885FAAH 4687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.